Core Viewpoint - He Yuan Bio experienced a stock price increase of 3.61% on November 3, with a trading volume of 1.603 billion yuan, indicating positive market sentiment towards the company [1]. Financing Summary - On November 3, He Yuan Bio had a financing buy-in amount of 154 million yuan, with a net financing purchase of 63.89 million yuan after repaying 90.45 million yuan [1]. - The total financing and securities balance for He Yuan Bio reached 256 million yuan, accounting for 4.87% of its circulating market value [1]. - There were no short-selling activities reported on November 3, with zero shares sold or repaid [1]. Company Overview - He Yuan Bio, established on November 16, 2006, is located in Wuhan, Hubei Province, and specializes in the research, production, and sales of products using rice endosperm cell recombinant protein expression technology [1]. - The company's main revenue source is recombinant human albumin, which constitutes 75.44% of its total revenue, while other products account for 24.56% [1]. Shareholder Information - As of October 28, He Yuan Bio had 47,100 shareholders, a significant increase of 84,075% compared to the previous period [2]. - The average number of circulating shares per shareholder decreased to 869 shares, down by 99.85% from the previous period [2]. Financial Performance - For the period from January to September 2025, He Yuan Bio reported a revenue of 19.66 million yuan, reflecting a year-on-year decrease of 8.51% [2]. - The company recorded a net profit attributable to shareholders of -121 million yuan, which is an 8.44% decrease compared to the same period last year [2].
禾元生物11月3日获融资买入1.54亿元，融资余额2.56亿元